Temsirolimus, an Inhibitor of Mammalian Target of RapamycinRINI, Brian I.Clinical cancer research. 2008, Vol 14, Num 5, pp 1286-1290, issn 1078-0432, 5 p.Article

Targeting the mTOR kinase domain: the second generation of mTOR inhibitorsZHANG, Yan-Jie; YANWEN DUAN; ZHENG, X. F. Steven et al.Drug discovery today. 2011, Vol 16, Num 7-8, pp 325-331, issn 1359-6446, 7 p.Article

Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxelSESSA, C; TOSI, D; COCEANI, N et al.Annals of oncology. 2010, Vol 21, Num 6, pp 1315-1322, issn 0923-7534, 8 p.Article

Identification of two novel inhibitors of mTOR signaling pathway based on high content screeningJUMING YAN; HONGYU ZHOU; LINGMEI KONG et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 4, pp 799-808, issn 0344-5704, 10 p.Article

Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trialBERK, Lori; MITA, Monica M; KREISBERG, Jeff et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 5, pp 1369-1377, issn 0344-5704, 9 p.Article

Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignanciesEYRE, Toby A; COLLINS, Graham P; GOLDSTONE, Anthony H et al.British journal of haematology. 2014, Vol 166, Num 3, pp 336-351, issn 0007-1048, 16 p.Article

Use of mTOR inhibitors in the treatment of malignanciesMOHINDRA, Nisha A; GILES, Francis J; PLATANIAS, Leonidas C et al.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 7, pp 979-990, issn 1465-6566, 12 p.Article

Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinomaHERBERGER, Beata; PUHALLA, Harald; LEHNERT, Martina et al.Clinical cancer research. 2007, Vol 13, Num 16, pp 4795-4799, issn 1078-0432, 5 p.Article

Combination Strategy Targeting the Hypoxia Inducible Factor-1α with Mammalian Target of Rapamycin and Histone Deacetylase InhibitorsVERHEUL, Henk M. W; SALUMBIDES, Brenda; VAN ERP, Karen et al.Clinical cancer research. 2008, Vol 14, Num 11, pp 3589-3597, issn 1078-0432, 9 p.Article

Inhibition of induced autophagy increases apoptosis of Nara-H cellsNAKAMURA, Osamu; HITORA, Toshiaki; AKISUE, Toshihiro et al.International journal of oncology. 2011, Vol 39, Num 6, pp 1545-1552, issn 1019-6439, 8 p.Article

Mammalian Target of Rapamycin Is the Key Effector of Phosphatidylinositol-3-OH-lnitiated Proliferative Signals in the Thyroid Follicular EpitheliumYEAGER, Nicole; BREWER, Charlene; CAI, Kathy Qi et al.Cancer research (Baltimore). 2008, Vol 68, Num 2, pp 444-449, issn 0008-5472, 6 p.Article

mTOR Signaling Pathway and mTOR Inhibitors in Cancer TherapyGOMEZ-PINILLOS, Alejandro; FERRARI, Anna C.Hematology/oncology clinics of North America. 2012, Vol 26, Num 3, issn 0889-8588, vii, 483-505 [24 p.]Article

Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATRQINGSONG LIU; CHUNXIAO XU; ERCAN, Dalia et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 8, pp 2574-2586, issn 0008-5472, 13 p.Article

From Node to Pathway Blockade: Lessons Learned From Targeting Mammalian Target of RapamycinHIDALGO, Manuel.Journal of clinical oncology. 2012, Vol 30, Num 1, pp 85-87, issn 0732-183X, 3 p.Article

Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitorsLIU, Kevin K.-C; BAILEY, Simon; DINH, Dac M et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 15, pp 5114-5117, issn 0960-894X, 4 p.Article

Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR InhibitorsPORCELLI, L; QUATRALE, A. E; MANTUANO, P et al.Current pharmaceutical design (Print). 2013, Vol 19, Num 5, pp 918-926, issn 1381-6128, 9 p.Article

Discovery and optimization of potent and selective imidazopyridine and imidazopyridazine mTOR inhibitorsPETERSON, Emily A; BOEZIO, Alessandro A; DUPONT, Michelle et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 15, pp 4967-4974, issn 0960-894X, 8 p.Article

Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitorFINLAY, M. Raymond V; BUTTAR, David; MUTTON, Simon et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 12, pp 4163-4168, issn 0960-894X, 6 p.Article

Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid CancerMANEGOLD, Philipp C; PARINGER, Carmen; KULKA, Ulrike et al.Clinical cancer research. 2008, Vol 14, Num 3, pp 892-900, issn 1078-0432, 9 p.Article

Regulation of mTOR by phosphatidic acid?FOSTER, David A.Cancer research (Baltimore). 2007, Vol 67, Num 1, pp 1-4, issn 0008-5472, 4 p.Article

Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimusDEL BUFALO, Donatella; CIUFFREDA, Ludovica; TRISCIUOGLIO, Daniela et al.Cancer research (Baltimore). 2006, Vol 66, Num 11, pp 5549-5554, issn 0008-5472, 6 p.Article

Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38XIAOCHUN BAI; DONGZHU MA; ANLING LIU et al.Science (Washington, D.C.). 2007, Vol 318, Num 5852, pp 977-980, issn 0036-8075, 4 p.Article

Clinical Outcomes in Kidney Transplant Recipients Receiving Long-Term Therapy With Inhibitors of the Mammalian Target of RapamycinCORTAZAR, F; MOLNARB, M. Z; ISAKOVA, T et al.American journal of transplantation (Print). 2012, Vol 12, Num 2, pp 379-387, issn 1600-6135, 9 p.Article

Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-provenIZZEDINE, H; ESCUDIER, B; ROUVIER, P et al.Annals of oncology. 2013, Vol 24, Num 9, pp 2421-2425, issn 0923-7534, 5 p.Article

Carcinomes cutanés après transplantation : La peau du transplanté - 2e partie: aspects cancérologiques = Cutaneous carcinomas after organ transplantationEUVRARD, Sylvie.Le Courrier de la transplantation. 2010, Vol 10, Num 2, pp 57-61, issn 1628-8319, 5 p.Article